



Effect of prebiotics, probiotics, and synbiotics on gut microbiome in diabetes among coastal communities

A. T. Rithi¹, Abhijit Mitra², Antara Banerjee², Divya Ilanchoorian³, Francesco Marotta⁴, Arun Kumar Radhakrishnan^{1*}

¹Department of Pharmacology, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Chennai, India; ²Medical Biotechnology lab, Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Chennai, India; ³Department of Community Medicine, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Chennai, India; ⁴ReGenera R&D International for Aging Intervention, Milan, Italy.

***Corresponding author:** Dr. Arun Kumar Radhakrishnan, Department of Pharmacology, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Chennai, India.

Submission Date: December 12th, 2023; **Acceptance Date:** January 2nd, 2023; **Publication Date:** January 8th, 2024


Please cite this article as: Rithi A. T., Mitra A., Banerjee A., Ilanchoorian D., Marotta F., Radhakrishnan A. K. Effect of prebiotics, probiotics, and synbiotics on gut microbiome in diabetes among coastal communities. *Functional Food Science* 2023; 4(1): 11-28. DOI: <https://doi.org/10.31989/ffs.v4i1.1271>

ABSTRACT

Cutting-edge research on oceans and human health is enhancing our comprehension of disease-causing organisms in coastal ecosystems. Coastal areas are affected by pollution resulting from the changes in hydrology and land utilization. In the coastal population, an elevated incidence of diabetes was observed. Diabetes mellitus is a prominent metabolic disease that is causing major burdens for patients as well as physicians. Diabetes is an intricate condition that encompasses several molecular pathways associated with the gut microbiome. The gut microbiome significantly influences the permeability of the gastrointestinal mucosa. Alterations in the wide range of gut microbiomes have been associated with various health issues including diabetes. The two major contributors to type 2 diabetes are insulin resistance and inflammation which may result in metabolic dysregulation due to dysbiosis. Due to gut dysbiosis, diabetes may show high prevalence in individuals living in coastal areas. The correlation between dysbiosis and diabetes can be made, especially considering probiotics have been demonstrated to have some impact in helping diabetic patients with their interrupted metabolism revert to normal. Probiotic intake has reportedly resulted in improved metabolic control among patients with type 2 diabetes. Prebiotics can be non-digestible carbohydrates that are naturally extracted or synthetically produced. Uses of synbiotics show a synergistic impact on type 2 diabetes by altering the gut environment. In coastal communities, the potential effects of probiotic, prebiotic, and synbiotic therapy on the gut microbiome of diabetic patients have been investigated. Although these therapies have demonstrated encouraging results in coastal areas, more research is needed to fully understand their implications for controlling diabetes in this setting. In this

review, we describe the role of the gut microbiome in diabetes patients residing in coastal regions and the underlying mechanisms that existed for analysing and predicting the function of the microbiome in diabetic people. The role of pre, pro, and synbiotics in type 1 and type 2 diabetes are precisely summarized.

Keywords: Type 1 diabetes, gut microbiome, type 2 diabetes, coastal region, dysbiosis, prebiotics, synbiotics, probiotics.



©FFC 2023. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License (<http://creativecommons.org/licenses/by/4.0>)

INTRODUCTION

One of the major global causes of disease and death is diabetes mellitus [1]. The chronic metabolic disorder is epitomized by hyper-glycemia, which is an increase in blood glucose levels resulting from a malfunction in the production of insulin or its activity [2]. The incidence rate is growing. High blood glucose levels and an increase in insulin resistance are characteristics of the disease [3]. Obesity and genetic changes are among the extrinsic and intrinsic factors that are combined to form the risk factors for diabetes mellitus. Numerous illnesses such as hypertension, diabetes, and cancer are linked to increased levels of free radicals and oxidative stress [4].

The microbiota of the gut influences immunological response and dietary intake, which are critical factors in determining general health [5]. The gastrointestinal tract

of humans normally has an enormous number of microorganisms, with an average of 10^{14} organisms per ml of luminal fluid. These microorganisms include more than 5,000 various types of bacteria. The gut microflora of healthy adults is primarily composed of six phyla: *Firmicutes*, *Proteobacteria*, *Bacteroidetes*, *Actinobacteria*, *Fusobacteria*, and *Verrucomicrobia* within the human intestinal tract [6]. Approximately 90% of these bacterial species may be divided into two major phyla, the *Firmicutes* and the *Bacteroidetes*, which are primarily composed of gram-positive and gram-negative bacteria. They play a crucial role in the nutritional absorption system and contribute to the reinforcement of the intestinal barrier [7]. Microbiome dysbiosis was a consistent phenomenon with diabetics, and it related to changes in the composition of the gut microbiome.

Reduced insulin sensitivity and inadequate glycemic control were caused by diabetes [8]. Several medical conditions, such as allergies, gastrointestinal inflammatory diseases, cancer, diabetes, cardiovascular diseases, and abnormalities in lipid metabolism, have been related to the gut microbiome composition.

Consequently, ocean and estuarine ecosystems play a significant role in influencing human exposure to a range of pathogenic microbes encompassing both indigenous marine pathogens and externally introduced microbial contaminants [9]. This also applies to industrial and agriculture pollutants of potential mutagenicity [10-12] and diabetogenic risk [13]. Ecosystems, functioning as primary reservoirs and influenced by terrestrial runoff, serve as protective barriers mitigating the impacts of surface activities on surrounding coastal environments and people communities [14]. Reductions in both the quantity and quality of crucial environments, sensitive to shifts in their surroundings, have consistently served as early indicators of widespread damage to coastal ecosystems [9]. While there are suggestions of a high prevalence of diabetes in coastal populations due to lifestyle factors, it is crucial to recognize the variations in reported prevalence in existing literature. Differences in screening criteria, age group composition, and the absence of lifestyle quantification demonstrated by Rao et al. (2010), highlight the complexity of this relationship [15]. Further research is needed to comprehensively explore the multifaceted factors influencing diabetes prevalence in coastal communities.

Probiotics may have a beneficial effect on gut flora, which could help with the treatment of a number of clinical disorders [16]. They have shown promise as supportive treatments for insulin resistance and contribute to a more balanced gut microbiome. Our understanding of the relationships between infections, coastal and marine habitats, and human health has greatly improved as a result of recent studies [9]. Prebiotics are a group of dietary substances that are

categorized together based on their capacity to stimulate the growth and/or activity of particular healthy bacteria in genetically modified organisms, rather than always on similar structural affinity [17]. The word "synbiotics" indicates the mutually enhancing interaction that occurs between the beneficial intestinal bacteria and the specific substrates that help them grow once they migrate from the gut to the intestines, so they can establish their dominance [18]. A study on synbiotics has resulted in the availability of various synbiotic products for individuals. Numerous ailments, including a result of atopic dermatitis, gastrointestinal conditions, liver encephalopathy, inflammatory bowel disease, metabolic syndrome, and type 2 diabetes, can be effectively treated with various synbiotic mixtures [19]. In this review, we summarize an overview of the gut microbiota's involvement in diabetes residing in coastal regions, and strategies that leverage probiotics, prebiotics, and synbiotics to both prevent and treat individuals with diabetes.

DIABETICS PEOPLE IN COASTAL REGIONS

In the coastal population, diabetes was found to be highly prevalent [15]. Kerala, a southern Indian state with a 20 percent type 2 diabetes frequency, is leading the nation in an epidemiological transformation and a predictor of the developments that will happen across the other parts of the country [20]. Type 1 diabetes also known as chronic autoimmune disease is caused by intricate interaction [21]. Based on epidemiological data, the prevalence of type 1 diabetes (T1D) ranges from 3% to 5% annually [22]. 8.2% of coastal people had diabetes, compared to 4.5% in the highlands ($p=0.03$) and 3.5% in the rainforest ($p<0.02$) region. An estimated 22.4% of the nation's population had impaired fasting glucose; it was more common in men than in women (28.3% vs. 19.1%; $p<0.001$), and it was more common in coastal areas (26.4%) than in the mountains (17.4%; $p=0.03$), but not in tropical areas (14.9%; $p=0.07$) [23]. A study prevalence

shows a total of 16% of people were found to have diabetes in the Karnataka coastal region. It was discovered that 18.8% of men and 14.4% of women had diabetes. 11.2% of participants self-reported having diabetes, and 4.8% of previously normal individuals had elevated fasting capillary blood glucose levels according to the screening criteria used in Karnataka coastal area [15]. Phenolic molecules are recognized as secondary metabolites that are necessary for defence responses, such as those involving antioxidant, anti-inflammatory, and antidiabetic properties [24].

In comparison to the non-coastal area, the coastal area's diabetes mortality shows a stronger relationship with environmental factors. The factors influencing

diabetes in coastal and non-coastal areas are summarized in Table 1. The interplay between the innate immune system and intestinal microbiota in the gut is an epigenetic element that might affect the susceptibility to type 1 diabetes. The potential exists that an interaction with a food antigen may trigger the primary immune system reaction leading to pancreatic damage [25]. Additionally, various factors, encompassing both genetic and environmental influences, contribute to an individual's susceptibility to T1D. Furthermore, the incidence of T1D is consistent across genders [26]. Existing evidence indicates that an imbalance in the gut microbiome is linked to an increased predisposition to type 1 Diabetes [22].

Table 1. Factors influencing diabetes in coastal and non-coastal regions

Factors	Coastal	Non-coastal	Reference
Mortality	The coastal areas showed a higher correlation between environmental variables and diabetes mortality than the non-coastal areas.		Zheng et al., 2023 [27]
Dietary pattern	Seafood is more easily accessible in coastal areas and can be a good source of lean protein and omega-3 fatty acids.	They depend on different sources of protein and the development and treatment of diabetes can be influenced by dietary habits.	Ssewanyana et al., 2018 [28]
Physical activity	Individuals living in coastal areas can get involved in water-based activities.	Lifestyle choices can impact the levels of physical activity, and non-coastal areas might offer different leisure opportunities.	Ssewanyana et al., 2018 [28]
Climate	Their climates might be milder, which would promote outdoor activities during the entire year.	More severe temperatures could impact individual outdoor activities and fitness routines.	Zheng et al., 2023 [27]
Socio-economic	Economic activities in the coastal region, such as fishing and tourism, can have an impact on socioeconomic variables and way of life.	Individual's different economic pursuits may have an effect on their ability to obtain medical treatment, dietary habits, and overall health.	Aswathy et al., 2017 [20]

Dysbiosis due to the interaction of gut microbiome, the environment, and genetic variations, may result in

impaired mucosal immune response and higher intestinal permeability in people with type 2 diabetes. These

factors could be associated with the development or aggravation of type 2 diabetes mellitus (T2DM) [29]. Some clinical research has demonstrated a link between lipopolysaccharides and the onset of type 2 diabetes. Simultaneously, the movement of viable bacteria from the intestinal barrier into the bloodstream seems to be associated with the progression of type 2 diabetes. A comprehensive human metagenome-wide association study has revealed noteworthy correlations between specific gut microbes, bacterial genes, and metabolic pathways in patients with type 2 diabetes (T2D) [25]. Administering appropriate doses of quercetin for protection against oxidative stress can be crucial in diabetes mellitus linked to the acidification of the internal environment observed in certain types of cancer [30]. One of the studies demonstrated the different parts of Kerala, India's southern state, have varying prevalence rates of type 2 diabetes; Kerala is going through an advanced phase of epidemiology transformation. Diabetes demonstrates similarities across communities [20].

Gut microbiome in coastal diabetic people: Coastal communities may be exposed to environmental factors, including pollutants or changes in coastal ecosystems that could influence the gut microbiome and inflammatory responses. The human gut microbiome can be negatively impacted by microplastic pollution in coastal areas [31] and is capable of causing IBD, IBS, obesity, and type 2 diabetes [32]. Low levels of *Bifidobacterium* and *Faecalibacterium prausnitzii*, two gram-positive bacteria with anti-inflammatory activities, are seen in diabetics [33]. The human host's gut

microbiome directly as well as indirectly promotes a number of crucial functions, such as the formation of the immune cells, the digestive breakdown of foods, the synthesis of vitamins, and the extraction of energy from inedible carbs [34]. A variety of metabolites such as short-chain fatty acids are produced from starch that is resistant to the gut microbiome and influences various pathways of signalling that are important for maintaining human health [35]. Dysbiosis is the alteration of the balance of the microbiota as a result of multiple factors such as inflammation in the gut, antibiotic consumption, menopause, stress, and contaminants [36]. Insulin resistance and other pre-diabetes disorders are influenced by gut microbiome composition [37]. The gut microbiota profiles of diabetics remain inconsistent and varied [25].

A decreased butyrate-producing bacteria (particularly *Roseburia intestinalis* and *Faecalibacterium prausnitzii*); moderate dysbiosis; pro-inflammatory ecology with a greater number of microbiota genes associated with oxidative stress, decreased activity of genes engaged in the synthesis of vitamin, and an elevated LPS concentration in serum are the main features of the microbiome of T2DM patients. In addition, there is an increase in the accessibility of the gastrointestinal tract [38].

Effect of metabolites on the gut and development of diabetes in coastal communities: In over a decade, numerous kinds of studies have examined various forms of expression between the gut microbiome and their hosts. The impact of metabolites on the gut microbiome concurring to cause diabetes is illustrated in Figure 1.




Figure 1. Impact of metabolites on gut microbiome causing diabetes

These investigations have explored the mechanisms, analysing and predicting the function of the microbiome in the inhibition of resistance to insulin, with a focus on components such as lipopolysaccharides (LPS) and short-chain fatty acids (SCFAs) [39]. Most of this research has focused on the activation of diabetes indicators, namely an immunological response and a low-grade inflammatory response, where gut microbiota and their metabolites play a key role [40]. Interestingly, it has been shown that by following healthy guidelines for diabetes, an indirect beneficial array of protective mechanisms against cancer may also arise [41].

Lipopolysaccharides (LPS): LPS originates from the cell wall of gram-negative bacteria [42]. Low-grade inflammation has been found to originate from LPS-promoting immune cells' and adipocytes' release of inflammatory cytokines. On the other hand, butyrate or acetic acid can alter the way of immune cells function [39]. Studies have shown that by stimulating the TLR4 signalling pathway, saturated fatty acids can cause low-grade inflammation and insulin resistance [43]. Various

studies have demonstrated the involvement of TLR2 in the inflammatory response when the signalling cascade activated by LPS-LBP-TLR4 is initiated [44]. The progression of type 2 diabetes appears to be significantly influenced by the strength of the intestinal wall. The primary role of the intestinal epithelium, which functions as a barrier, is to restrict the interplay throughout the primary specific immunity, the gut microbiome, and other body organs [45]. Investigations performed on animals have demonstrated that lipopolysaccharide (LPS) has a role in the control of diabetes-associated pathways, which are distinguished by the elevated inflammatory response [46].

Short chain fatty acids (SCFAs): SCFAs are generated when non-digestible dietary fibers mostly acetate, propionate, and butyrate are fermented by bacteria in the intestinal tract [4, 39]. The range of bacteria in various sediment layers in coastal areas is identified by the concentration of saturated carbon filler (SCFA), butyrate indicating the impact on bacterial growth and composition of bacterial community [47]. Studies done in

mice have demonstrated that SCFA dietary supplementation enhances insulin sensitivity, rectifies dyslipidemia, prevents weight gain, and enhances energy expenditure in diet-induced obese mice [48]. In clinical investigations, it has been observed that dietary fiber promotes the production of SCFAs by the gut microbiome, whereas many other potential producers are comparatively diminished in individuals with type 2 diabetes [49]. According to a metagenomic study, individuals with type 2 diabetes who have not been treated with metformin may exhibit a reduction in the abundance of butyrate-producing genera, such as *Roseburia* spp and *Subdoligranulum* spp [50]. Moreover, the number of butyrate-producing bacteria is lesser in prediabetic persons than in healthy individuals, indicating that a lack of these types of bacteria may be one of the progenitors of diabetes [51].

Role of bile acids signalling: The liver synthesizes bile acids, which undergo enzymatic metabolism by gut microbiota to transform into secondary bile acids [52]. The bile acids generated by the gut microbiota may affect human glucose and lipid metabolism by modulating signaling via bile acid receptors [49]. Furthermore, it has been shown that obese T2DM people have elevated circulation levels of bile acids [53], and these levels have been demonstrated to correlate with BMI [54]. Furthermore, it highlights the importance of bile acids in improving glucose balance during RYGB (Roux-en-Y Gastric Bypass), since FXR mutant mice's metabolism does not improve following vertical sleeve gastrectomy (VSG) [55].

Branched chain amino acids (BCAA): Branched-chain amino acids (BCAA) are regarded as predicting markers for T2D and may be associated with an increased chance of developing T2D [56]. The substantial correlation between BCAA and diabetes, along with the possible role of amino acid metabolism in the initial stages of diabetes, was also shown by extensive research [57]. Investigation

carried out on rats has indicated that insulin resistance is also induced by high-fat nutritional supplementation with BCAA [58]. The finding that including more branched-chain amino acids in one's diet raises the risk of type 2 diabetes and insulin resistance has been confirmed through human research [59]. Phosphatidylinositol 3-kinase (PI3K) activation and increased oxidation of free fatty acids are considered to be the mechanisms behind BCAA-induced insulin resistance [60]. The specific mechanism is still unknown, though, and needs further investigation.

Role of butyrate: *Faecalibacterium prausnitzii*, also known as *F. prausnitzii*, has been identified as the most prevalent butyrate-producing bacterium by analysis of human fecal samples. The intestinal microflora of type 2 diabetes patients has less *F. prausnitzii* and *Roseburia* than the intestinal microflora of healthy people, according to extensive metagenomic association studies conducted across a range of populations [61]. Furthermore, studies suggest that elevated *F. prausnitzii* levels help reduce insulin resistance and inflammatory symptoms [39]. *Roseburia* spp, another butyrate-producing microbe is essential for immune system function and intestinal health maintenance because it controls T cell balance constantly by creating butyric acid [62]. Moreover, prediabetic subjects have fewer butyrate-producing bacteria in their bodies than healthy subjects [51].

Biotics role in diabetics of coastal areas: The role of probiotics, prebiotics, and synbiotics in individuals with diabetes, including those in coastal communities, is an area of research interest. These interventions aim to modulate the composition and activity of the gut microbiome, potentially influencing metabolic health. Multiple investigations have discovered that probiotics, prebiotics, and synbiotics enhance gut microbiome homeostasis, maintaining the gut barrier integrity, and changing the immune responses. These compounds also

have a positive impact on host health by reducing the risk of infections from pathogens, and conditions related to obesity, type 2 diabetes, IBD, colon cancer, etc [63-64].

The role of pro, pre, and synbiotics in the gut microbiome of diabetes is shown in Figure 2.




Figure 2. Role of probiotics, prebiotics, and synbiotics in diabetes

Probiotic: Probiotics are live microorganisms, mainly bacteria and yeast, which confer health benefits to the host when consumed in adequate amounts [65]. Probiotics can assist in reducing weight through enhancing the number and diversity of the microbiome, controlling immune responses, and boosting metabolic rates [66]. Probiotics can be found naturally in certain fermented foods like kefir, yogurt, sauerkraut, kimchi, and miso [67-68]. Coastal communities with unique dietary patterns, such as a high intake of seafood or specific local foods, may have distinct microbial profiles. Probiotics could potentially contribute to maintaining or restoring a healthy gut microbiota in these populations. Additionally, they are available as dietary supplements in the form of capsules, tablets, and powders [69]. Many species belonging to the genera *Lactobacillus* and *Bifidobacterium* shows an essential benefit in maintaining a healthy gut microbiota and an exciting

intestinal habitat. Furthermore, probiotics customized to a particular strain also promote good health outcomes, such as immune system maintenance [70-71]. Probiotic components linked to beneficial outcomes encompass a range of cellular components, including but not limited to peptidoglycan, teichoic acids, polysaccharides, fimbrial/pili contents, and bacteriocins [72]. *Lactobacillus* (Firmicutes phylum) and *Bifidobacterium* (Actinobacteria phylum) are the probiotic strains that have been found to have the most beneficial effects on human glucose metabolism [73-76]. Probiotics, particularly *Lactobacillus* spp, have been scientifically shown in two recent reviews [32, 77] to have beneficial impacts on the management and prevention of T1D and T2D.

According to Ziegler et al. (2021), treating dysbiosis at an early age may promote immunological tolerance and inhibit the development of β -cell autoimmunity [78]. From 7 days to 12 months of age, they advised giving

Bifidobacterium infantis to infants who had an increased genetic risk of type 1 diabetes (T1D) in order to test the hypothesis. The main goal of the study was to determine if this intervention could reduce the overall level of β -cell autoantibodies in children [78]. Wang et al. (2022) [79] demonstrated that the randomized controlled trials (RCT) of 59 type 1 diabetes patients aged from 6 to 18 underwent insulin injection therapy and probiotics of

three strains such as *L. salivarius* subsp. *Salicinius* AP-32 and *L. johnsonii* MH-68 isolated from human gut and *Bifidobacterium animalis* subsp. *Lactis* CP-9 from breast milk. Results of this study showed that probiotics play a major role in reducing the glucose level and immune-inflammatory cytokines were inhibited [79]. Numerous studies show the beneficial effects of probiotics to prevent and cure diabetes are illustrated in Table 2.

Table 2. Positive effects of probiotics strains in diabetes

DIABETES TYPE	PROBIOTICS STRAINS	OUTCOME	REFERENCE
Type 1 Diabetes mellitus	<i>Bifidobacterium infantis</i> to infants	↑Immune tolerance ↓development of β -cell autoimmunity	Ziegler et al., 2021 [78]
	<i>L. salivarius</i> subsp. <i>Salicinius</i> AP-32, <i>L. johnsonii</i> MH-68, <i>Bifidobacterium animalis</i> subsp. <i>Lactis</i> CP-9	↓Immune inflammatory cytokines ↓synthesis of glucose	Wang et al., 2022 [79]
	<i>Bifidobacterium longum</i> , <i>Lactobacterium bulagricumi</i> , <i>Streptococcus thermophilus</i>	↑ FBG ↑ Low-density lipoprotein cholesterol ↑HbA1c ↑MSG	Zhang et al., 2023 [80]
Type 2 Diabetes mellitus	<i>L. acidophilus</i> La-5, <i>B. animalis</i> subsp <i>lactis</i> BB-12	↑Glycaemic control ↑synthesis of acetic acid ↓Inflammatory cytokines (TNF- α , resistin)	Tonucci et al., 2017 [81]
	<i>L. acidophilus</i> La-5, <i>B. lactis</i> Bb12, <i>L. bulgaricus</i>	↑ Fasting blood glucose ↑Antioxidant	Ejtahed et al., 2012 [82]
	<i>L. plantarum</i> A7, <i>Bifidobacterium</i>	↑ HbA1c ↑Fasting insulin	Firouzi et al., 2016 [83]
	<i>Lactobacillus acidophilus</i> , <i>L. casei</i> , <i>L. rhamnosus</i> , <i>L. bulgaricus</i> , <i>Bifidobacterium breve</i> , <i>B. longum</i> , <i>Streptococcus thermophilus</i>	↑ Plasma total GSH ↑Fasting plasma glucose ↓Serum hs-CRP	Asemi et al., 2013 [84]

Probiotics exhibit potential in curing Type 2 Diabetes Mellitus (T2DM), and several potential pathways have been identified [85]. Probiotic ingestion

frequently improves the symptoms of Type 2 diabetes mellitus (T2DM), such as elevated peripheral insulin sensitivity, reduced endoplasmic reticulum stress,

lowered systemic LPS levels, as also shown in advanced liver disease [86], and enhanced intestinal integrity [86]. In an animal model, probiotics such as *L. rhamnosus*, *L. acidophilus*, and *B. bifidum* treatment decreased *Firmicutes* and increased *Bacteroidetes* abundance [87]. Fifteen randomized controlled trials (RCTs) including nine hundred and two individuals were examined in the systematic review of probiotic therapies to treat Type 2 diabetes mellitus (T2DM). The results of the meta-analysis showed that among those with type 2 diabetes, probiotic therapy was linked with reduced levels of insulin resistance, fasting blood glucose levels (FBG), and HbA1c [88]. According to a meta-analysis that examined their Probiotics effects on type 2 diabetes. The results show that probiotics significantly reduce systolic and diastolic blood pressure, total cholesterol, triglyceride levels, C-reactive protein (CRP), HbA1c, fasting insulin levels, and fasting plasma glucose. Probiotic intake did not significantly affect levels of low-density lipoprotein (LDL) or body mass index (BMI), but it was associated with higher levels of high-density lipoprotein (HDL) [65].

Prebiotic: Non-digestible carbohydrates, referred to as prebiotics, have an impact on the gut microbiome and immune system. Prebiotics exist in numerous forms that can be divided into many different groups [89]. High amylose maize starch (HAMS) is a prebiotic and dietary fibre that provides a unique way to modify the gut microbiota to mitigate diabetes [90]. Fructans low-calorie content and prebiotic activity constitute its beneficial components. One form of non-digestible fibre with prebiotic properties is referred to as galactooligosaccharides [91]. Women took an insulin supplement for 19 days. The results showed a significant increase in *Bifidobacteria*, which are useful through

fermentation, and a decrease in Enterococci and *Enterobacteriaceae*, but no statistically significant changes in *Bacteroides*, *Clostridium*, or *Faecalibacterium prausnitzii* [17]. This type of interaction has a role in developing autoimmune diseases, such as type 1 diabetes [92]. Substrates known as prebiotics are those that host bacteria specifically use for nutritional benefits [17]. To maintain the host's gut microbiota in a healthy state, they promote the development as well as enzymatic activation of intestinal microbes [93]. Wang et al. (2019) study shows that the effect of inulin-type fructans by using a meta-analysis of 33 Randomised controlled trials of 1346 participants significantly showed the decreasing level of fasting blood glucose, glycosylated hemoglobin (HbA1c), fasting insulin (FINS), and homeostasis model assessment-insulin resistance (HOMA-IR) in type 2 diabetic patients [94]. Some clinical investigations are illustrated in Table 3.

Synbiotic: A product that has both probiotics and prebiotics is referred to as a synbiotic. Prebiotics and probiotics work in harmony to benefit the host in an effective manner [100]. The use of synbiotics may be considered in coastal populations with diabetes to enhance the effectiveness of probiotic interventions and promote a balanced gut microbiota. Synbiotics help the host by either triggering microbial metabolic processes that support human health or specifically encouraging the growth of probiotics [101]. This increases the ability to survive the process of probiotics in the digestive tract and improves the environmental conditions of the gut. Multiple investigations demonstrate the digestive and urinary tract health benefits of synbiotics, as well as their potential anticancer and antiaging properties [18].

Table 3. Various clinical studies showing the beneficial role of prebiotics and synbiotics in type 2 diabetes

DIABETIC TYPE	PREBIOTICS	OUTCOME	REFERENCE
Type 2 diabetes mellitus	Inulin-type Fructans	↓ Fasting blood glucose ↓ HbA1c ↓ Fasting insulins ↓ HOMA-IR	Wang et al., 2019 [94]
	Inulin	↑ Fasting blood glucose ↑ HOMA-IR ↑ HbA1c	Zhang et al., 2022 [95]
DIABETIC TYPE	SYNBIOTIC STRAINS	OUTCOME	REFERENCE
Type 2 diabetes	<i>B. bifidum</i> , <i>L. acidophilus</i> , 2g oligofructose	↓ Fasting glycemia ↑ HDL-C	Moroti et al., 2012 [96]
	<i>Lactobacillus acidophilus</i> , <i>Bifidobacter bifidum</i> , <i>Bifidobacter lactis</i> , and <i>Bifidobacter longum</i> , 6g inulin	↑ HDL-C ↑ (LDL)/HDL	Kassaian et al., 2017 [97]
	<i>Lactobacillus acidophilus</i> , <i>Lactobacillus casei</i> , <i>Bifidobacterium bifidum</i> and 0.8g inulin	↓ blood glucose ↓ insulin levels ↓ insulin resistance ↑ insulin sensitivity	Soleimani et al., 2018 [98]
	<i>Bacillus Coagulans</i> , <i>Lactobacillus rhamnosus</i> , <i>Lactobacillus acidophilus</i> and fructooligosaccharide	↓ Insulin level ↓ HOMA-IR CRP ↓ HOMA-β levels	Velayati et al., 2021 [99]

Positive effects of synbiotics on T2DM control have been demonstrated through various research, which is encouraging for T2DM patients. Insulin resistance and glucose metabolism in the host may be improved by using synbiotics to alter the gut microbiota [102]. Using the meta-analysis, they investigated the impacts of probiotics and synbiotics on biochemical variables among individuals with prediabetes and type 2 diabetes, such as fasting insulin levels, FPG, HbA1c, HOMA-IR, and OGTT. Despite an important variation in glucose levels following OGTT, probiotic and synbiotic consumption enhanced QUICKI and lowered FPG, HbA1c, fasting insulin, and

HOMA-IR [103]. Some clinical investigations are illustrated in Table 3. The effects of probiotics, prebiotics, and synbiotics in type 1 Diabetes mellitus patients were investigated by systemic review and meta-analysis shows the insulin demands, C-peptide, and serum HbA1c did not significantly improve. Supplementing with probiotics may be an additional therapeutic approach for type 1 diabetes [104].

CONCLUSION

Compared to non-coastal regions, coastal regions have a high prevalence of diabetes attributed to the lifestyle

manners and dietary patterns of the coastal communities. Fatal incidence in diabetes are more strongly correlated with pollution exposure in coastal areas. It became known that co-morbid conditions including hypertension and hypercholesterolemia could independently predict an increased risk of diabetes. Several antigens isolated from the gut microbiome may play a role in the regulation of immunological disorders. Functional disruptions could be a factor in the autoimmune death of β -cells in the pancreas that results in T1D, and elevated inflammatory cytokine expression could be linked to resistance to insulin and T2D. Research on diabetic people and gut microbiome has evolved progressively, transitioning from initial studies, which established a robust association, to delving into causality and potential underlying mechanisms such as the role of butyrate, bile acids, lipopolysaccharides, short-chain fatty acids, and Branched-chain amino acids. In this review, we summarized the concept that probiotics, prebiotics, and synbiotics might be beneficial for managing and preventing Type 1 and Type 2 diabetes by altering the gut microbiota which has been confirmed. The data from the clinical trials and experimental research shows the beneficial effects of probiotics, prebiotics, and synbiotics in type 1 and type 2 diabetic people with either increased or decreased in FBG, HbA1c, immune tolerance, levels of plasma glucose, and fasting insulin were also discussed. Along with biotics, some organic compounds like squalene also prevent type 2 diabetes [105]. A profound, evidence-based approach, taking care of qualitative aspects of functional foods and bioactive compounds, as well as their extraction and testing methodologies represent a mandatory path to follow, as envisaged in the Functional Food Center consensus [106].

Abbreviations: DM: Diabetes mellitus, T2DM: type 2 diabetes mellitus, FBG: fasting blood glucose, CRP: c-reactive protein, SCFA: short-chain fatty acids, BCAA:

branched-chain amino acids, LPS: lipopolysaccharides, BMI: body mass index, VSG: vertical sleeve gastrectomy, RYGB: Roux-en-Y gastric bypass, PI3k: phosphatidylinositol 3-kinase, RCT: Randomised control trials, LDL: Low-density lipoprotein, HDL: High-density lipoprotein, MSG: mean sensor glucose, TNF- α : Tumor necrosis factor alpha, GSH- glutathione, LBP- lipopolysaccharide-binding protein, FXR- Farnesoid X receptor, FPG: fasting plasma glucose.

Funding: The corresponding author acknowledge the grants sanctioned to Prof. Dr. Arun Kumar Radhakrishnan (PI) from the National Centre for Coastal Research, Govt. of India with the sanction order No. MoES/ICMAM-PD/Suppl. order/81/2017 under the research programme- Seawater Quality Monitoring (SWQM/COMAPS).

Competing interests: None. All authors declare that there are no conflicts of / or competing interests.

Ethics Approval and Consent to Participate: Non-Applicable. This research does not involve human/animal participants, human/ animal material, or human data.

Consent for publication: All authors have approved the final version of the manuscript and given consent for publication.

Authors' Contributions: AKR and AB designed the study and conceptualized the work. AB, RAT, and AM conducted data analysis and wide-ranging aspects of the manuscript preparation and pictorial representations. AKR, AB, DI, and FM have critically reviewed the draft manuscript and provided feedback on data analyses. All authors read and approved the final manuscript.

Acknowledgment: The authors are thankful to Chettinad Academy of Research and Education (CARE) for providing

the infrastructural support and to the National Centre for Coastal Research, Govt. of India for providing the financial support.

REFERENCES:

1. Zhou C, Byard, RW: An analysis of the morbidity and mortality of diabetes mellitus in a forensic context. *J Forensic Sci* 2017; 63(4), 1149-1154. DOI: <https://doi.org/10.1111/1556-4029.13674>
2. Sameer A, Bandy M, Nissar S: Pathophysiology of diabetes: an overview. *Avicenna J Med* 2020; 10(4), 174-188. DOI: https://doi.org/10.4103/ajm.ajm_53_20
3. Deshpande AD, Harris-Hayes M, Schootman M: Epidemiology of diabetes and diabetes-related complications. *Phys Ther* 2008; 88(11), 1254-1264. DOI: <https://doi.org/10.2522/ptj.20080020>
4. Ibrahim HR, Hitotsumatsu A and Miyata T: Identification of potent antioxidant bioactive peptides from the soluble proteins of chicken egg yolk. *Functional food science* 2023; 3(6):63–63. DOI: <https://doi.org/10.31989/ffs.v3i6.1110>.
5. AL-Ishaq RK, Samuel SM, Büsselberg D: The influence of gut microbial species on diabetes mellitus. *Int J Mol Sci* 2023; 24(9), p.8118. DOI: <https://doi.org/10.3390/ijms24098118>
6. Fuller S, Beck E, Salman H, Tapsell L: New horizons for the study of dietary fiber and health: a review. *Plant Foods Hum Nutr* 2016, 71(1), 1-12. DOI: <https://doi.org/10.1007/s11130-016-0529-6>
7. Neis E, Dejong C, Rensen S: The role of microbial amino acid metabolism in host metabolism. *Nutrients* 2015; 7(4), 2930-2946. DOI: <https://doi.org/10.3390/nu7042930>
8. Sadagopan A, Mahmoud A, Begg M, Tarhuni M, Fotso, M, Gonzalez, NA, Sanivarapu, RR et al: Understanding the role of the gut microbiome in diabetes and therapeutics targeting leaky gut: a systematic review. *Cureus* 2023; e41559. DOI: <https://doi.org/10.7759/cureus.41559>
9. Stewart JR, Gast RJ, Fujioka RS, Solo-Gabriele HM, Meschke JS, Amaral-Zettler LA, del Castillo E et al: The coastal environment and human health: microbial indicators, pathogens, sentinels and reservoirs. *Environ Health* 2008; 7(Suppl 2), p.S3. DOI: <https://doi.org/10.1186/1476-069x-7-s2-s3>
10. Saravanakumar K, SivaSantosh S, Sathiyaseelan A, Naveen KV, AfaanAhamed MA, Zhang X, Priya VV et al: Unraveling the hazardous impact of diverse contaminants in the marine environment: Detection and remedial approach through nanomaterials and nano-biosensors. *J Hazard Mater* 2022; 433:128720. DOI: <https://doi.org/10.1016/j.jhazmat.2022.128720>
11. Paithankar JG, Saini S, Dwivedi S, Sharma A, Chowdhuri DK: Heavy metal associated health hazards: An interplay of oxidative stress and signal transduction. *Chemosphere* 2021; 262:128350. DOI: <https://doi.org/10.1016/j.chemosphere.2020.128350>
12. Yaduvanshi SK, Srivastava N, Marotta F, Jain S, Yadav H: Evaluation of micronuclei induction capacity and mutagenicity of organochlorine and organophosphate pesticides. *Drug Metab Lett* 2012; 6(3):187-197. DOI: <https://doi.org/10.2174/1872312811206030006>
13. Tyagi S, Siddarth M, Mishra BK, Banerjee BD, Urfi AJ, Madhu SV: High levels of organochlorine pesticides in drinking water as a risk factor for type 2 diabetes: a study in north India. *Environ Pollut.* 2021; 271:116287. DOI: <https://doi.org/10.1016/j.envpol.2020.116287>
14. Holland AD, Sanger D, Gawle CP, Lerberg SB, Santiago MS, Riekerk GHM, Zimmerman L: Linkages between tidal creek ecosystems and the landscape and demographic attributes of their watersheds. *J Exp Mar Biol Ecol* 2004; 298(2), 151-178. DOI: [https://doi.org/10.1016/s0022-0981\(03\)00357-5](https://doi.org/10.1016/s0022-0981(03)00357-5)
15. Rao C, Kamath V, Shetty A, Kamath A: A study on the prevalence of type 2 diabetes in coastal Karnataka. *Int J Diabetes Dev Ctries* 2010; 30(2), 80-85. DOI: <https://doi.org/10.4103/0973-3930.62597>
16. Hemarajata P, Versalovic J: Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. *Therap Adv Gastroenterol* 2012; 6(1), 39-51. DOI: <https://doi.org/10.1177/1756283x12459294>
17. Megur A, Daliri EB, Baltrikienė D, Burokas A: Prebiotics as a tool for the prevention and treatment of obesity and diabetes: classification and ability to modulate the gut microbiota. *Int J Mol Sci.* 2022; 23(11), 6097. DOI: <https://doi.org/10.3390/ijms23116097>
18. Jiang H, Cai M, Shen B, Wang Q, Zhang T, Zhou X: Synbiotics and gut microbiota: new perspectives in the treatment of type 2 diabetes mellitus. *Foods* 2022; 11(16), p.2438. DOI: <https://doi.org/10.3390/foods11162438>
19. Núñez-Sánchez MA, Herisson FM, Cluzel GL, Caplice NM: Metabolic syndrome and synbiotic targeting of the gut microbiome. *Curr Opin Food Sci* 2021; 41, 60-69. DOI: <https://doi.org/10.1016/j.cofs.2021.02.014>
20. Aswathy S, Lohidas V, Paul N, Anish TS, Narayanan T, Oldenburg B: Prevalence and Social Determinants of Type 2 Diabetes in a Coastal Area of Kerala, India. *J Endocrinol Diabetes* 2017; 4(3). DOI: <https://doi.org/10.15226/2374-6890/4/3/00181>

21. Calabrese CM, Valentini A, Calabrese G: Gut Microbiota and Type 1 Diabetes Mellitus: The Effect of Mediterranean Diet. *Front Nutr* 2021; 7. DOI: <https://doi.org/10.3389/fnut.2020.612773>
22. Zheng P, Li Z, Zhou Z: Gut microbiome in type 1 diabetes: A comprehensive review. *Diabetes Metab Res Rev* 2018; 34(7), p.e3043. DOI: <https://doi.org/10.1002/dmrr.3043>
23. Seclen SN, Rosas ME, Arias AJ, Huayta E, Medina CA. Prevalence of diabetes and impaired fasting glucose in Peru: report from PERUDIAB, a national urban population-based longitudinal study. *BMJ Open Diabetes Res Care* 2015; 3(1), e000110. DOI: <https://doi.org/10.1136/bmidrc-2015-000110>
24. M Abd Elgadir, Sridevi Chigurupati and Abdalbasit Adam Mariod: Selected potential pharmaceutical and medical benefits of phenolic compounds: Recent advances. *Functional food science* 2023; 3(7):108–108. DOI: <https://doi.org/10.31989/ffs.v3i7.1118>.
25. Blandino G, Inturri R, Lazzara F, Di Rosa M, Malaguarnera L: Impact of gut microbiota on diabetes mellitus. *Diabetes Metab* 2016; 42(5), 303-315. DOI: <https://doi.org/10.1016/j.diabet.2016.04.004>
26. Yurkovetskiy L, Burrows M, Khan, AA, Graham L, Volchkov P, Becker L, Antonopoulos D et al: Gender bias in autoimmunity is influenced by microbiota. *Immunity* 2013; 39(2), 400-412. DOI: <https://doi.org/10.1016/j.immuni.2013.08.013>
27. Zheng W, Chu J, Bambrick H, Wang N, Mengersen K, Guo X and Hu W: Impact of environmental factors on diabetes mortality: A comparison between inland and coastal areas. *Science of The Total Environment* 2023, 904:166335. DOI: <https://doi.org/10.1016/j.scitotenv.2023.166335>
28. Ssewanyana D, Abubakar A, van Baar A, Mwangala PN and Newton CR: Perspectives on Underlying Factors for Unhealthy Diet and Sedentary Lifestyle of Adolescents at a Kenyan Coastal Setting. *Frontiers in Public Health* 2018, 6. DOI: <https://doi.org/10.3389/fpubh.2018.00011>
29. Razmpoosh E, Javadi A, Ejtahed HS, Mirmiran P, Javadi M, Yousefinejad A: The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: A randomized placebo -controlled trial. *Diabetes Metab Syndr* 2019; 13(1), 175–182. DOI: <https://doi.org/10.1016/j.dsx.2018.08.008>
30. Beata Cizmarova, Beata Hubkova and Birkoa A: Quercetin as an effective antioxidant against superoxide radical. *Functional food science* 2023; 3(3):15–15. DOI: <https://doi.org/10.31989/ffs.v3i3.1076>.
31. Bull MJ,Plummer NT: Part 1: The Human Gut Microbiome in Health and Disease. *Integrative medicine* 2014; 13(6):17–22. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566439/>
32. Fackelmann G, Pham CK, Rodríguez Y, Mallory ML, Provencher JF, Baak JE, Sommer S: Current levels of microplastic pollution impact wild seabird gut microbiomes. *Nature Ecology & Evolution* 2023; 1–9. DOI: <https://doi.org/10.1038/s41559-023-02013-z>
33. Gomes AC, Bueno AA, de Souza RGM, Mota JF: Gut microbiota, probiotics and diabetes. *Nutr J* 2014; 13(60). DOI: <https://doi.org/10.1186/1475-2891-13-60>
34. Sharma S, Tripathi P: Gut microbiome and type 2 diabetes: where we are and where to go? *J Nutr Biochem* 2019; 63, 101–108. DOI: <https://doi.org/10.1016/j.jnutbio.2018.10.003>
35. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM: The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res* 2013; 54(9), 2325–2340. DOI: <https://doi.org/10.1194/jlr.r036012>
36. Hegde S, Lin YM, Golovko G, Khanipov K, Cong Y, Savidge T, Fofanov Y et al: Microbiota dysbiosis and its pathophysiological significance in bowel obstruction. *Sci Rep* 2018; 8(13044). DOI: <https://doi.org/10.1038/s41598-018-31033-0>
37. Roager HM, Vogt JK, Kristensen M, Hansen LBS, Ibrügger S, Mærkedahl RB, Bahl MI: Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial. *Gut* 2017; 68(1), 83–93. DOI: <https://doi.org/10.1136/gutjnl-2017-314786>
38. Sabatino A, Regolisti G, Cosola C, Gesualdo L, Fiaccadori E: Intestinal microbiota in type 2 diabetes and chronic kidney disease. *Curr Diab Rep* 2017; 17(16). DOI: <https://doi.org/10.1007/s11892-017-0841-z>
39. Li WZ, Stirling K, Yang JJ, Zhang L: Gut microbiota and diabetes from correlation to causality and mechanism. *World J Diabetes* 2020; 11(7):293-308. DOI: <https://doi.org/10.4239/wjd.v11.i7.293>
40. Saad MJA, Santos A, Prada PO: Linking gut microbiota and inflammation to obesity and insulin resistance. *physiology* 2016, 31(4):283-293. DOI: <https://doi.org/10.1152/physiol.00041.2015>
41. Rastmanesh R, Hejazi J, Marotta F, Hara N: Type 2 diabetes: a protective factor for prostate cancer? An overview of

- proposed mechanisms. Clin Genitourin Cancer 2014; 12(3):143-148. DOI: <https://doi.org/10.1016/j.clgc.2014.01.001>
42. Blaut M, Klaus S: Intestinal microbiota and obesity. Handb Exp Pharmacol 2012; 209:251-273. DOI: https://doi.org/10.1007/978-3-642-24716-3_11
 43. Rogero M, Calder P: Obesity, inflammation, toll-like receptor 4 and fatty acids. Nutrients 2018; 10(4):432. DOI: <https://doi.org/10.3390/nu10040432>
 44. Gholizadeh P, Mahallei M, Pormohammad A, Varshochi M, Ganbarov K, Zeinalzadeh E, Yousefi B et al: Microbial balance in the intestinal microbiota and its association with diabetes, obesity and allergic disease. Microb Pathog 2019; 127:48-55. DOI: <https://doi.org/10.1016/j.micpath.2018.11.031>
 45. Odenwald MA, Turner JR: The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol 2017; 14(1):9-21. DOI: <https://doi.org/10.1038/nrgastro.2016.169>
 46. Delzenne NM, Cani PD: Gut microbiota and the pathogenesis of insulin resistance. Curr Diab Rep 2011; 11(3):154-159. DOI: <https://doi.org/10.1007/s11892-011-0191-1>
 47. Sun C, Zhou L, Liang QY, Wang X, Lei Y, Xu Z, Wang F, Chen G, Du Z, Mu DS: Short-chain fatty acids (SCFAs) as potential resuscitation factors that promote the isolation and culture of uncultured bacteria in marine sediments. Marine Life Science and Technology 2023, 5(3):400-414. DOI: <https://doi.org/10.1007/s42995-023-00187-w>
 48. Meijnikman AS, Gerdes VE, Nieuwdorp M, Herrema H: Evaluating causality of gut microbiota in obesity and diabetes in humans. Endocr Rev 2017; 39(2):133-153. DOI: <https://doi.org/10.1210/er.2017-00192>
 49. Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, Fu H et al: Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science 2018; 359(6380):1151-1156. DOI: <https://doi.org/10.1126/science.aao5774>
 50. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E et al: Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528(7581):262-266. DOI: <https://doi.org/10.1038/nature15766>
 51. Allin KH, Tremaroli V, Caesar R, Jensen BAH, Damgaard MTF, Bahl MI, Licht TR, et al: Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia 2018; 61(4):810-820. DOI: <https://doi.org/10.1007/s00125-018-4550-1>
 52. Fiorucci S, Distrutti E: Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders. Trends Mol Med 2015; 21(11):702-714. DOI: <https://doi.org/10.1016/j.molmed.2015.09.001>
 53. Vincent RP, Omar S, Ghozlan S, Taylor DR, Cross G, Sherwood RA, Fandriks L et al: Higher circulating bile acid concentrations in obese patients with type 2 diabetes. Ann Clin Biochem 2013; 50(4):360-364. DOI: <https://doi.org/10.1177/0004563212473450>
 54. Prinz P, Hofmann T, Ahnis A, Elbelt U, Goebel-Stengel M, Klapp BF, Rose M et al: Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Front Neurosci 2015; 9. DOI: <https://doi.org/10.3389/fnins.2015.00199>
 55. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, Wilson-Pérez HE et al: FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014; 509(7499):183-188. DOI: <https://doi.org/10.1038/nature13135>
 56. Giesbertz P, Daniel H: Branched-chain amino acids as biomarkers in diabetes. Curr Opin Clin Nutr Metab Care 2016; 19(1):48-54. DOI: <https://doi.org/10.1097/mco.0000000000000235>
 57. Wang TJ, Larson MG, Vasani RS, Cheng S, Rhee EP, McCabe E, Lewis GD et al: Metabolite profiles and the risk of developing diabetes. Nature Medicine 2011; 17(4):448-453. DOI: <https://doi.org/10.1038/nm.2307>
 58. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM et al: A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9(4):311-326. DOI: <https://doi.org/10.1016/j.cmet.2009.02.002>
 59. Asghari G, Farhadnejad H, Teymoori F, Mirmiran P, Tohidi M, Azizi F: High dietary intake of branched-chain amino acids is associated with an increased risk of insulin resistance in adults. J Diabetes 2018; 10(5):357-364. DOI: <https://doi.org/10.1111/1753-0407.12639>
 60. Kawaguchi T, Izumi N, Charlton MR, Sata M: Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 2011; 54 (3):1063-1070. DOI: <https://doi.org/10.1002/hep.24412>
 61. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, Krakoff J: Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94(1):58-65. DOI: <https://doi.org/10.3945/ajcn.110.010132>
 62. Tamanai-Shacoori Z, Smida I, Bousarghin L, Loreal O, Meuric V, Fong SB, Bonnaure-Mallet M et al: *Roseburia* spp.: a

- marker of health? *Future Microbiol* 2017; 12(2):157–170. DOI: <https://doi.org/10.2217/fmb-2016-0130>
63. Mohania D, Kansal VK, Kumar M, Nagpal R, Yamashiro Y, Marotta F: Modulation of expression of programmed death-1 by administration of probiotic dahi in DMH-induced colorectal carcinogenesis in rats. *Acta Biomed* 2013; 84 (2), 102-109
 64. Liu Y, Wang J, Wu C: Modulation of gut microbiota and immune system by probiotics, pre-biotics, and post-biotics. *Front Nutr* 2022; 8. DOI: <https://doi.org/10.3389/fnut.2021.634897>
 65. Kocsis T, Molnar B, Nemeth D, Hegyi P, Szakacs Z, Balint A, Garami A et al: Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. *Sci Rep* 2020; 10(1). DOI: <https://doi.org/10.1038/s41598-020-68440-1>
 66. Williams K, Oo T, and Martirosyan D: Exploring the effectiveness of lactobacillus probiotics in weight management: A literature review. *Functional food sciences* 2023; 3(5):45-54. DOI: <https://doi.org/10.31989/ffs.v3i5.1115>.
 67. Dahiya D, Nigam PS: Probiotics, prebiotics, synbiotics, and fermented foods as potential biotics in nutrition improving health via microbiome-gut-brain axis. *Fermentation* 2022; 8(7):303. DOI: <https://doi.org/10.3390/fermentation8070303>
 68. Palsdottir H: 11 Probiotic Foods That Are Super Healthy. Healthline. [<https://www.healthline.com/nutrition/11-super-healthy-probiotic-foods>] Retrieved December 11, 2023
 69. Fenster K, Freeburg B, Hollard C, Wong C, Laursen RR, Ouwehand A: The production and delivery of probiotics: a review of a practical approach. *Microorganisms* 2019; 7(3):83. DOI: <https://doi.org/10.3390/microorganisms7030083>
 70. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L et al: Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol* 2014; 11(8):506-514. DOI: <https://doi.org/10.1038/nrgastro.2014.66>
 71. McFarland LV, Evans CT, Goldstein EJC: Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. *Front Med* 2018; 5(124). DOI: <https://doi.org/10.3389/fmed.2018.00124>
 72. Turrone F, Ventura M, Butto LF, Duranti S, O'Toole PW, Motherway MO, van Sinderen D: Molecular dialogue between the human gut microbiota and the host: a *Lactobacillus* and *Bifidobacterium* perspective. *Cell Mol Life Sci* 2013; 71(2):183-203. DOI: <https://doi.org/10.1007/s00018-013-1318-0>
 73. Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Vilsbøll T, Knop FK, Holst JJ: The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. *Am J Physiol Regul Integr Comp Physiol* 2015; 309(5): R544-R551. DOI: <https://doi.org/10.1152/ajpregu.00123.2015>
 74. Lighthouse J, Naito Y, Helmy A, Hotten P, Fuji H, Min CH, Yoshioka M et al: Endotoxemia and benzodiazepine-like substances in compensated cirrhotic patients: a randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation. *Hepatol Res*. 2004; 28(3):155-160. DOI: <https://doi.org/10.1016/j.hepres.2003.11.005>
 75. Hamari S, Kirveskoski T, Glumoff V, Kulmala P, Simell O, Knip M, Ilonen J et al: CD4+T-cell proliferation responses to wheat polypeptide stimulation in children at different stages of type 1 diabetes autoimmunity. *Pediatr Diabetes* 2015; 16(3):177-188. DOI: <https://doi.org/10.1111/pedi.12256>
 76. Kahaly GJ, Hansen MP: Type 1 diabetes associated autoimmunity. *Autoimmun Rev* 2016; 15(7):644-648. DOI: <https://doi.org/10.1016/j.autrev.2016.02.017>
 77. Razmpoosh E, Javadi M, Ejtahed HS, Mirmiran P: Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review. *Diabetes Metab Res Rev* 2015; 32(2):143–168. DOI: <https://doi.org/10.1002/dmrr.2665>
 78. Ziegler AG, Arnolds S, Kölln A, Achenbach P, Berner R, Bonifacio E, Casteels K et al: Supplementation with *Bifidobacterium longum* subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. *BMJ open* 2021; 11(11), p.e052449. DOI: <https://doi.org/10.1136/bmjopen-2021-052449>
 79. Wang CH, Yen HR, Lu WL, Ho HH, Lin WY, Kuo YW, Huang YY et al: Adjuvant probiotics of *Lactobacillus salivarius* subsp. salicinicus AP-32, *L. johnsonii* MH-68, and *Bifidobacterium animalis* subsp. lactis CP-9 attenuate glycemic levels and inflammatory cytokines in patients with type 1 diabetes mellitus. *Front Endocrinol* 2022; 13, p.754401. DOI: <https://doi.org/10.3389/fendo.2022.754401>
 80. Zhang X, Zhang Y, Luo L, Le Y, Li Y, Yuan F, Wu Y et al: The beneficial effects of a multispecies probiotic supplement on

- glycaemic control and metabolic profile in adults with type 1 diabetes: a randomised, double-blinded, placebo-controlled pilot-study. *Diabetes Metab Syndr Obes* 2023; 16, 829–840. DOI: <https://doi.org/10.2147/dmso.s400119>
81. Tonucci LB, dos Santos OKM, de Oliveira LL, Ribeiro, RSM, Martino DHS: Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. *Clin Nutr* 2017; 36(1), 85–92. DOI: <https://doi.org/10.1016/j.clnu.2015.11.011>
 82. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid, V: Probiotic yogurt improves antioxidant status in type 2 diabetic patients. *Nutrition* 2012; 28(5), 539-543. DOI: <https://doi.org/10.1016/j.nut.2011.08.013>
 83. Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak MY: Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. *Eur J Nutr* 2016; 56(4), 1535–1550. DOI: <https://doi.org/10.1007/s00394-016-1199-8>
 84. Asemi Z, Zare Z, Shakeri H, Sabihi S, Esmailzadeh A: Effect of multispecies probiotic supplements on metabolic profiles, hs-crp, and oxidative stress in patients with type 2 diabetes. *Ann. Nutr. Metab* 2013; 63(1-2), 1–9. DOI: <https://doi.org/10.1159/000349922>
 85. Panwar H, Rashmi HM, Batish VK, Grover S: Probiotics as potential biotherapeutics in the management of type 2 diabetes - prospects and perspectives. *Diabetes Metab Res Rev* 2013; 29(2), 103–112. DOI: <https://doi.org/10.1002/dmrr.2376>
 86. Balakumar M, Prabhu D, Sathishkumar C, Prabu P, Rokana N, Kumar R, Raghavan S et al: Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice. *European Journal of Nutrition* 2016; 57(1), 279–295. DOI: <https://doi.org/10.1007/s00394-016-1317-7>
 87. Bagarolli RA, Tobar N, Oliveira AG, Araújo TG, Carvalho BM, Rocha GZ, Vecina JF et al: Probiotics modulate gut microbiota and improve insulin sensitivity in DIO mice. *J Nutr Biochem* 2017; 50, 16-25. DOI: <https://doi.org/10.1016/j.inutbio.2017.08.006>
 88. Tao YW, Gu YL, Mao XQ, Zhang L, Pei YF: Effects of probiotics on type II diabetes mellitus: a meta-analysis. *J Transl Med* 2020; 18(1). DOI: <https://doi.org/10.1186/s12967-020-02213-2>
 89. Lordan C, Thapa D, Ross RP, Cotter PD: Potential for enriching next-generation health-promoting gut bacteria through prebiotics and other dietary components. *Gut Microbes* 2019; 11(1), 1–20. DOI: <https://doi.org/10.1080/19490976.2019.1613124>
 90. Ismail HM, Spall M, Evans-Molina C, DiMeglio LA: Evaluating the effect of prebiotics on the gut microbiome profile and β cell function in youth with newly diagnosed type 1-diabetes: protocol of a pilot randomized controlled trial. *Pilot and Feasibility Studies* 2023; 9(1). DOI: <https://doi.org/10.1186/s40814-023-01373-4>
 91. Mitmesser S, Combs M: Prebiotics: inulin and other oligosaccharides. In *The Microbiota in Gastrointestinal Pathophysiology*, ed. MH Floch, Y Ringel, WA Walker 2017; 201–208. Boston: Academic
 92. Verduci E, Mameli C, Amatruda M, Petitti A, Vizzuso S, El Assadi F, Zuccotti G et al (2020): Early nutrition and risk of type 1 diabetes: the role of gut microbiota. *Front Nutr* 2020; 7. DOI: <https://doi.org/10.3389/fnut.2020.612377>
 93. Terpou A, Papadaki A, Lappa IK, Kachrimanidou V, Bosnea LA, Kopsahelis N: Probiotics in food systems: significance and emerging strategies towards improved viability and delivery of enhanced beneficial value. *Nutrients* 2019; 11(7), p.1591. DOI: <https://doi.org/10.3390/nu11071591>
 94. Wang L, Yang H, Huang H, Zhang C, Zuo HX, Xu P, Niu YM et al: Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose-response meta-analysis of 33 randomized controlled trials. *J Transl Med* 2019, 17(1). DOI: <https://doi.org/10.1186/s12967-019-02159-0>
 95. Zhang R, Xiao Y, Yan J, Yang W, Wu X, Mei Z, Zhou Z: Effects of berberine plus inulin on diabetes care in patients with latent autoimmune diabetes in adults: protocol for a randomized controlled trial. *Front Endocrinol (Lausanne)* 2022; 13, 876657. DOI: <https://doi.org/10.3389/fendo.2022.876657>
 96. Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC, Sivieri K: Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. *Lipids Health Dis* 2012;11(29). DOI: <https://doi.org/10.1186/1476-511X-11-29>
 97. Kassaian N, Aminorroaya A, Feizi A, Jafari P, Amini M: The effects of probiotic and synbiotic supplementation on metabolic syndrome indices in adults at risk of type 2 diabetes: study protocol for a randomized controlled trial. *Trials* 2017; 18(1). DOI: <https://doi.org/10.1186/s13063-017-1885-8>

98. Soleimani A, Motamedzadeh A, Zarrati Mojarrad M, Bahmani F, Amirani E, Ostadmohammadi V, Tajabadi-Ebrahimi M, Asemi Z: The effects of synbiotic supplementation on metabolic status in diabetic patients undergoing hemodialysis: a randomized, double-blinded, placebo-controlled trial. *Probiotics Antimicrob* 2018; DOI: <https://doi.org/10.1007/s12602-018-9499-3>
99. Velayati A, Kareem I, Sedaghat M, Sohrab G, Nikpayam O, Hedayati M, Abhari K et al: Does symbiotic supplementation which contains *Bacillus Coagulans* *Lactobacillus rhamnosus*, *Lactobacillus acidophilus* and *fructooligosaccharide* has favourable effects in patients with type-2 diabetes? A randomised, double-blind, placebo-controlled trial. *Archives of Physiology and Biochemistry* 2021; 1–8. DOI: <https://doi.org/10.1080/13813455.2021.1928225>
100. Sarao LK, Arora M: Probiotics, prebiotics, and microencapsulation: a review. *Crit Rev Food Sci Nutr* 2015; 57(2), 344–371. DOI: <https://doi.org/10.1080/10408398.2014.887055>
101. Short C, Salminen S, Roberfroid M: Probiotics and prebiotics in health. Springer eBooks 2001; 119-140. DOI: https://doi.org/10.1007/978-3-642-56623-3_9
102. Han JL, Lin HL: Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective. *World J Gastroenterol* 2014; 20(47), 17737–17745. DOI: <https://doi.org/10.3748/wjg.v20.i47.17737>
103. Naseri K, Saadati S, Ashtary-Larky D, Asbaghi O, Ghaemi F, Pashayee-Khamene F, Yari Z et al: Probiotics and synbiotics supplementation improve glycemic control parameters in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials. *Pharmacological Research* 2022; 184, 106399. DOI: <https://doi.org/10.1016/j.phrs.2022.106399>
104. Moravejolahkami AR, Shakibaei M, McGrattan A, Sharma M: Probiotics, prebiotics, and synbiotics in type 1 diabetes mellitus: A systematic review and meta-analysis of clinical trials 2023. DOI: <https://doi.org/10.1002/dmrr.3655>
105. Mirmiranpour H, Ashoori MR, Mikaeili AS, Pezeshki S, Serani A, Vassar R, Martirosyan D: The effect of squalene on lipid profile and some oxidative biomarkers in patients with type 2 diabetes mellitus. *Functional Food Science* 2022; 2(7):144. DOI: <https://doi.org/10.31989/ffs.v2i7.949>
106. Martirosyan D, Lampert T, Lee M: A comprehensive review on the role of food bioactive compounds in functional food science. *Functional Food Science* 2022; 3(2): 64-78. DOI: <https://doi.org/10.31989/ffs.v2i3.906>